Publications & News

WilmerHale Advises Millennium Pharmaceuticals in $8.8 Billion Acquisition by Takeda

April 10, 2008

A team of WilmerHale lawyers advised Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) in connection with its proposed $8.8 billion acquisition by Takeda Pharmaceutical Company Limited (TSE: 4502) through a cash tender offer. The deal is the largest overseas acquisition by a Japanese drug manufacturer.

Serving as Millennium’s M&A counsel in the transaction are WilmerHale lawyers David Redlick, Hal Leibowitz, Jeffrey Hermanson, Brian Johnson, Emily Babalas, Jason Kropp and Sonia Bednarowski. The M&A team is assisted by antitrust partners William Kolasky and Sven Voeckler, and tax partners William Schmidt and Robert Burke.

WilmerHale has served as primary outside counsel to Millennium since the early 1990s. Millennium is a leading biopharmaceutical company based in Cambridge, Massachusetts that markets VELCADE, a novel cancer product, and has oncology and inflammation product candidates in various stages of development.

Click here for Millennium Pharmaceutical’s complete press release.